The one factor NWBO might overlook is a sense of urgency. In my opinion, they likely have a far superior product that will initially be merged into a protocol with chemotherapy and radiation (and surgery in the case of DCVAX-L).
However, while big pharma likely has inferior products to offer as their proposed adjuvants, they can market their upcoming products as if they were comparable to DCVax.
In other words, I hope NWBO does not try to get cute with their timing, and instead proceeds full steam ahead.
I understand most of the upcoming catalysts are pretty much out of their timing control right now, but the catalysts that can be placed on fast forward should be.
News 
Market Data 
Discover 
AI
